From: Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity
Neutropenia, G-CSF support
5 (17.9 %), 11 (39.3 %)
Anemia
7 (25.0 %)
Thrombocytopenia